24 Results
Sort By:
Published on March 20, 2024
Researchers from Boston University Chobanian & Avedisian School of Medicine have discovered that the signaling molecule chemokine-like factor (CKLF) plays a key role in promoting immunosuppression and tumor aggression in neuroblastoma and potentially in other tumors with abnormal activation of the MYCN oncoprotein. “The MYCN oncoprotein drives the initiation, progression,…
Published on January 10, 2024
A new, more effective, treatment may have been found for neuroblastoma, which is one of the most common cancers of childhood. Using single-cell sequencing, researchers at the Princess Máxima created a detailed atlas of neuroblastoma tumors at both the individual tumor and immune cell level. Using this atlas, the team…
Published on May 17, 2023
Research led by Baylor College of Medicine and Texas Children’s Cancer Center shows hopeful results in a first-in-human phase I clinical trial using genetically engineered natural killer T cell (NKT) immunotherapy to treat neuroblastoma. Neuroblastoma is the most common cancer in infants, arising from immature nerve cells and predominantly affecting…
Published on April 4, 2023
An international team of clinical researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University, and the New Approaches to Neuroblastoma Therapy (NANT) Consortium, has released data from a Phase I study showing that the tyrosine kinase inhibitor (TKI) lorlatinib is a safe and effective treatment…
Published on August 24, 2022
Almost half of children with high-risk neuroblastoma harbor extra copies of the gene MYCN (MYCN amplified), the primary driver of neuroblastoma and its resistance to therapy. However, no available therapies directly target MYCN. In a paper published in Nature Communications, researchers from Baylor College of Medicine delved into understanding metabolic vulnerabilities of…
Published on June 8, 2022
A retrospective study led by University of Chicago researchers has shown that “bridge” therapy between induction and consolidation treatments benefits high-risk neuroblastoma patients who respond poorly to induction. “There are approximately 700–800 cases of neuroblastoma each year and about half of these cases will be high-risk,” first author Ami Desai,…
Published on September 23, 2021
A new immunotherapy using modified cells targeting two different antigens was highly effective in a mouse model of human neuroblastoma, according to a study led by researchers from the UNC Lineberger Comprehensive Cancer Center and the UNC School of Medicine. The new treatment restricted tumor regrowth and also prevented the…
Published on June 1, 2021
Scientists from the Wellcome Sanger Institute and the University of Cambridge have discovered that that genomic changes following platinum chemotherapy for neuroblastoma can cause secondary blood cancers like leukemias in treated children. The researchers, whose study was published in the journal Blood, hope this discovery may lead to treatment changes…
Published on February 8, 2021
Researchers from the Wellcome Sanger Institute, Great Ormond Street Hospital (GOSH), and the Princess Máxima Center for Pediatric Oncology, have unveiled new research indicating that all neuroblastomas arise from a single type of embryonic cell, known as sympathoblasts, which could point to new therapeutic options. The discovery that all neuroblastomas…
Published on February 10, 2020
Researchers in Japan have developed a new method to monitor children at risk of neuroblastoma recurrence after treatment. This new method utilizes droplet digital PCR (ddPCR) to monitor residual disease in high risk patients, a methodology that could be utilized to evaluate treatment response and facilitate early diagnosis of tumor…
Published on July 29, 2019
An international research team has discovered that the jumonji domain-containing 6 (JMJD6) gene plays a critical role in neuroblastoma tumorigenesis. In addition, in work that opens up a potential new target for the treatment of neuroblastoma, they showed that when JMJD6’s expression was reduced, neuroblastoma cell proliferation and survival in…
Published on April 3, 2024
Adaptimmune’s pivotal SPEARHEAD-1 trial has shown that the T cell receptor therapy afami-cel effectively targets metastatic synovial sarcoma and myxoid round cell liposarcoma, potentially opening the door for other solid tumors to be treated with T cell therapies. “Synovial sarcoma is a rare cancer with historically limited treatment options and…
Published on November 21, 2023
Research led by the University of Texas at El Paso and Bodoland University in India shows a special type of quantum dot made from caffeic acid, which can be extracted from coffee grounds, could be very effective at preventing the onset of neurodegeneration. The research is still at an early…
Published on September 20, 2023
New research shows Tau is a possible cause of long COVID “brain fog.” Another study suggests specific genes passed on from Neanderthals confer extra risk of severe COVID-19 symptoms. Studies have shown that contracting COVID-19 can worsen Alzheimer’s disease in patients. The infection may also make people more prone to…
Published on June 28, 2023
A team of Austrian researchers using single-cell sequencing has uncovered how cancer cells prevent cells in their environment from fighting the tumor. The research, published in Nature Communications and led by Sabine Taschner-Mandl, PhD, head of the Tumor Biology Group at St. Anna Children’s Cancer Research Institute (St. Anna CCRI),…